This is consistent with our findings that low MAP1LC3A expression in ESCC may be related to the aggressiveness of malignant cells, whereas high MAP1LC3A expression increases the risk of poor prognosis and may be related to the proliferation of tumor cells. This evidence concerns the gene MAP1LC3A and neoplasm.